Not intended for U.S. and UK Media - American College of Cardiology 66th Annual Scientific Session (ACC.17):

Berlin, March 6, 2017 - Bayer AG and its development partner Janssen
Pharmaceuticals, Inc. announced today that results from the Phase III EINSTEIN
CHOICE study with the oral Factor Xa inhibitor rivaroxaban (Xarelto®) will be
presented as part of a Late-Breaking Clinical Trial Session on Saturday, March
18th as part of the upcoming American College of Cardiology 66th Annual
Scientific Session, which will take place in Washington, D.C., USA, from March
17 to 19.

The Phase III EINSTEIN CHOICE study investigated the efficacy and safety of two
doses of rivaroxaban (10 mg once daily and 20 mg once daily) versus aspirin
(100 mg once daily) for the extended treatment of patients with a venous
thromboembolism (VTE), who had previously completed 6 to 12 months of
anticoagulation therapy.(1) VTE includes pulmonary embolism and deep vein
thrombosis and is the third most common cause of cardiovascular death after
heart attack and stroke.(2) Existing Guidelines recommend anticoagulation
therapy for three months or longer for patients with an initial VTE.(3)
However, the risk for patients with unprovoked VTE or with ongoing risk factors
experiencing a second event is up to 10 percent in the first year if treatment
is stopped.(4) In clinical practice physicians need to carefully assess how
long to provide anticoagulation therapy for the individual patient following
the initial treatment phase and also which treatment regimen may best align
with the benefit-risk profile of the individual patient.

Additionally, results from the Phase II GEMINI ACS 1 study will be presented as
part of the same Late-Breaking Clinical Trial session at ACC.17. GEMINI ACS 1
assessed the safety of dual antithrombotic therapy of rivaroxaban 2.5 mg twice
daily in combination with clopidogrel or ticagrelor compared with dual
antiplatelet therapy of aspirin 100 mg once daily in combination with
clopidogrel or ticagrelor in patients with a recent acute coronary syndrome
(ACS).

- The Prescribing of Antiplatelet Therapy Only in Patients With Nonvalvular
Atrial Fibrillation: Results From the GARFIELD-AF Registry
o Moderated Poster Session 1223M - Stroke and AF: Thinking About the Heart

Rivaroxaban is the most broadly indicated non-vitamin K antagonist oral
anticoagulant (NOAC) and is marketed under the brand name Xarelto®. Xarelto is
approved for seven indications, protecting patients across more venous and
arterial thromboembolic (VAT) conditions than any other NOAC:

- The prevention of stroke and systemic embolism in adult patients with
non-valvular atrial fibrillation (AF) with one or more risk factors

- The prevention of atherothrombotic events (cardiovascular death, myocardial
infarction or stroke) after an Acute Coronary Syndrome in adult patients with
elevated cardiac biomarkers and no prior stroke or transient ischaemic attack
(TIA) when co-administered with acetylsalicylic acid (ASA) alone or with ASA
plus clopidogrel or ticlopidine

Whilst licences may differ from country to country, across all indications
Xarelto is approved in more than 130 countries.

Rivaroxaban was discovered by Bayer, and is being jointly developed with
Janssen Research & Development, LLC. Xarelto is marketed outside the U.S. by
Bayer and in the U.S. by Janssen Pharmaceuticals, Inc. (Janssen Research &
Development, LLC and Janssen Pharmaceuticals, Inc. are part of the Janssen
Pharmaceutical Companies of Johnson & Johnson).

Anticoagulant medicines are potent therapies used to prevent or treat serious
illnesses and potentially life-threatening conditions. Before initiating
therapy with anticoagulant medicines, physicians should carefully assess the
benefit and risk for the individual patient.

Responsible use of Xarelto is a very high priority for Bayer, and the company
has developed a Prescribers Guide for physicians and a Xarelto Patient Card for
patients to support best practice.

Bayer is a global enterprise with core competencies in the Life Science fields
of health care and agriculture. Its products and services are designed to
benefit people and improve their quality of life. At the same time, the Group
aims to create value through innovation, growth and high earning power. Bayer
is committed to the principles of sustainable development and to its social and
ethical responsibilities as a corporate citizen. In fiscal 2016, the Group
employed around 115,200 people and had sales of EUR 46.8 billion. Capital
expenditures amounted to EUR 2.6 billion, R&D expenses to EUR 4.7 billion.
These figures include those for the high-tech polymers business, which was
floated on the stock market as an independent company named Covestro on October
6, 2015. For more information, go to www.bayer.com.

Our online press service is just a click away: press.bayer.com
Follow us on Facebook: http://www.facebook.com/pharma.bayer
Follow us on Twitter: https://twitter.com/BayerPharma

Forward-looking statements
This release may contain forward-looking statements based on current
assumptions and forecasts made by Bayer management. Various known and unknown
risks, uncertainties and other factors could lead to material differences
between the actual future results, financial situation, development or
performance of the company and the estimates given here. These factors include
those discussed in Bayer's public reports which are available on the Bayer
website at www.bayer.com. The company assumes no liability whatsoever to update
these forward-looking statements or to conform them to future events or
developments.